25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Development of the Flu-PRO: a patient-reported outcome (PRO) instrument to evaluate symptoms of influenza

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          To develop content validity of a comprehensive patient-reported outcome (PRO) measure following current best scientific methodology to standardize assessment of influenza (flu) symptoms in clinical research.

          Methods

          Stage I (Concept Elicitation): 1:1 telephone interviews with influenza-positive adults (≥18 years) in the US and Mexico within 7 days of diagnosis. Participants described symptom type, character, severity, and duration. Content analysis identified themes and developed the draft Flu-PRO instrument. Stage II (Cognitive Interviewing): The Flu-PRO was administered to a unique set of influenza-positive adults within 14 days of diagnosis; telephone interviews addressed completeness, respondent interpretation of items and ease of use.

          Results

          Samples: Stage I: N = 46 adults (16 US, 30 Mexico); mean (SD) age: 38 (19), 39 (14) years; % female: 56 %, 73 %; race: 69 % White, 97 % Mestizo. Stage II: N = 34 adults (12 US, 22 Mexico); age: 37 (14), 39 (11) years; % female: 50 %, 50 %; race: 58 % White, 100 % Mestizo. Symptoms: Symptoms identified by >50 %: coughing, weak or tired, throat symptoms, congestion, headache, weakness, sweating, chills, general discomfort, runny nose, chest (trouble breathing), difficulty sleeping, and body aches or pains. No new content was uncovered during Stage II; participants easily understood the instrument.

          Conclusions

          Results show the 37-item Flu-PRO is a content valid measure of influenza symptoms in adults with a confirmed diagnosis of influenza. Research is underway to evaluate the suitability of the instrument for children and adolescents. This work can form the basis for future quantitative tests of reliability, validity, and responsiveness to evaluate the measurement properties of Flu-PRO for use in clinical trials and epidemiology studies.

          Related collections

          Most cited references6

          • Record: found
          • Abstract: found
          • Article: not found

          Perspectives on patient-reported outcomes : content validity and qualitative research in a changing clinical trial environment.

          Patient-reported outcomes (PROs) represent the voice of the patient in drug and device evaluation. As such, the outcomes selected for evaluation must be relevant to the patient, and the instruments used to capture them must have sound measurement properties. This paper discusses the role of qualitative research methods in assuring PRO clarity and content validity in a clinical trial environment characterized by evolving regulatory policy, new advances in technology and increasingly diverse samples within global clinical trials. Three important PRO measurement issues influenced by these changes are addressed: (i) endpoint selection and instrument development; (ii) the adaptation of instruments for electronic administration; and (iii) conceptual equivalence of measures across diverse samples. These are viewed as interrelated issues of content validity that can be addressed through the appropriate and rigorous application of qualitative research methods. Focus groups, cognitive debriefing, user acceptance testing and translation methodologies are discussed as ways to address and document the content validity of PRO instruments and ensure the empirical data representing the voice of the patient is sound.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims

            (2006)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Development and validation of the Influenza Intensity and Impact Questionnaire (FluiiQ™).

              Clinical trials of new agents to reduce the severity and impact of influenza require accurate assessment of the effect of influenza infection. Because there are limited high-quality adult influenza Patient Reported Outcomes (PRO) measures, the aim was to develop and validate a simple but comprehensive questionnaire for epidemiological research and clinical trials. Construct and item generation was guided by the literature, concept mapping, focus groups, and interviews with individuals with laboratory-confirmed influenza and expert physicians. Items were administered to 311 people with influenza-like illness (ILI) across 25 US sites. Analyses included classic psychometrics, structural equation modeling (SEM), and Rasch analyses. Concept mapping generated 149 concepts covering the influenza experience and clustered into symptoms and impact on daily activities, emotions, and others. Items were drafted using simplicity and brevity criteria. Eleven symptoms from the literature underwent review by physicians and patients, and two were removed and one added. The symptoms domain factored into systemic and respiratory symptoms, whereas the impact domains were unidimensional. All domains displayed good internal consistency (Cronbach α ≥ 0.8) except the three-item respiratory domain (α = 0.48). A five-factor SEM indicated excellent fit where systemic, respiratory, and daily activities domains differentiated patients with ILI or confirmed influenza. All scales were responsive over time. Patient and clinician consultations resulted in an influenza PRO measure with high validity and good overall evidence of reliability and responsiveness. The Influenza Intensity and Impact Questionnaire (FluiiQ™) will improve the evaluation of existing and future agents designed to prevent or control influenza infection by increasing the breadth and depth of measurement in this field. Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                +301-768-6711 , john.powers@nih.gov
                mlga08@gmail.com
                nancy.leidy@evidera.com
                mary.p.fairchok.ctr@mail.mil
                arosenberg@mail.nih.gov
                andreshernandez57@gmail.com
                sonja.stringer@evidera.com
                christina.m.schofield2.civ@mail.mil
                rozu76@hotmail.com
                katherine.kim@evidera.com
                patrick.j.danaher6.mil@mail.mil
                hilda.ortega.innsz@gmail.com
                elizabeth.bacci@evidera.com
                nathaniel.stepp@med.navy.mil
                galindofraga@yahoo.com
                Kristina.j.stclair.mil@mail.mil
                michael.rajnik@usuhs.edu
                erin.mcdonough@med.navy.mil
                michelande.ridore@gmail.com
                john.arnold@med.navy.mil
                emillar@idcrp.org
                gmrps@servidor.unam.mx
                Journal
                BMC Infect Dis
                BMC Infect. Dis
                BMC Infectious Diseases
                BioMed Central (London )
                1471-2334
                5 January 2016
                5 January 2016
                2015
                : 16
                : 1
                Affiliations
                [ ]Clinical Monitoring and Research Program, Clinical Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21702 in support of the Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD USA
                [ ]Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
                [ ]Evidera, Bethesda, MD USA
                [ ]Infectious Disease Clinical Research Program, Uniformed Services University, Bethesda, MD USA
                [ ]Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD USA
                [ ]Madigan Army Medical Center, Tacoma, WA USA
                [ ]Instituto Nacional de Enfermedades Infecciosas, Mexico City, Mexico
                [ ]Hospital General Dr. Manuel Gea González, Mexico City, Mexico
                [ ]San Antonio Health System, San Antonio, TX USA
                [ ]Camp Lejeune, Jacksonville, NC USA
                [ ]Naval Medical Center Portsmouth, Portsmouth, VA USA
                [ ]Walter Reed National Military Medical Center, Bethesda, MD USA
                [ ]Naval Health Research Center, San Diego, CA USA
                [ ]Naval Medical Center San Diego, San Diego, CA USA
                [ ]5601 Fishers Lane, Room 4D50, Rockville, MD 20852 USA
                Article
                1330
                10.1186/s12879-015-1330-0
                4700740
                26729246
                c85ddcd6-6348-4e2a-a133-8898c9548381
                © Powers et al. 2015

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 27 July 2015
                : 21 December 2015
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100000054, National Cancer Institute (US);
                Award ID: HHSN261200800001E
                Award Recipient :
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2016

                Infectious disease & Microbiology
                influenza,symptoms,patient-reported outcomes,endpoints,outcome assessments,content validity

                Comments

                Comment on this article